Research Article
Therapeutic Effects of Milk Thistle (Silybum marianum L.) and Artichoke (Cynara scolymus L.) on Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Rats

Aida Doostkam 1, Mohammad Fathalipour 2, Mohammad Hossein Anbardar 3, Azar Purkhosrow 4, and Hossein Mirkhani 4,5

1Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
4Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
5Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence should be addressed to Hossein Mirkhani; mirkhanh@sums.ac.ir

16 May 2021; Revised 19 January 2022; Accepted 24 January 2022; Published 11 February 2022

1. Introduction

Diabetes mellitus (DM) is a common metabolic disorder characterized by high plasma glucose over a long period due to defects in insulin synthesis, insulin receptor, or post-receptor signaling pathway events. Chronic hyperglycemia is the leading cause of microvascular and macrovascular complications of DM [1].

More than 90% of diabetic patients with diabetes are afflicted by type 2 diabetes mellitus (T2DM). In type 2 diabetes, elevated plasma glucose and free fatty acid levels lead to oxidative stress, β-cell dysfunction, insulin resistance, and metabolic syndrome [2, 3]. One of the manifestations of these cellular and molecular disorders is a nonalcoholic fatty liver disease (NAFLD), a chronic liver disease [4].

NAFLD is a pathological condition characterized by hepatic fat accumulation not caused by the consumption of alcohol. It consists of a spectrum of liver diseases, from simple steatosis to steatohepatitis, hepatic fibrosis, chronic cirrhosis, and hepatocellular carcinoma [5]. In addition to
type 2 diabetes, obesity and hypertriglyceridemia are the main coexisting conditions associated with NAFLD [6].

Milk thistle (Silybum marianum L.) is originally a native plant of Southern Europe through Asia with the active compound silymarin, a natural flavonoid. Silymarin consists of silybin, silychristin, silydianin, and isosilybin [7], and it is widely used as a nonprescription agent in liver diseases [8]. Several studies have indicated its promising antifibrotic activity in experimental liver injury [8, 9]. Reports show that it decreases oxidative stress by increasing glutathione levels [10]. Silymarin may decrease hepatic inflammation by inhibiting the lipo-oxygenase cycle and reducing leukotrienes and Kupffer cell function in animals [11]. In Iran, silymarin is sold as tablets under the proprietary name of Livergol®.

Artichoke (Cynara scolymus L.) is a perennial plant native to the Mediterranean region. Anti-hyperlipidemic effects of artichoke extract have been documented in clinical and experimental studies [12, 13]. Further studies have shown the inhibitory effects of artichoke extract on HMG-CoA reductase [14] and phosphatidate phosphohydrolase [15] in the cholesterol and triglyceride biosynthesis pathways, respectively. Some reports show that the artichoke extract reduces oxidative stress by reducing reactive oxygen species production and lipid peroxidation [13, 16]. Several researchers have indicated that artichoke promotes insulin secretion, sensitivity, and plasma glucose reduction in animal models of diabetes [17, 18]. In addition to this effect, the administration of artichoke extract has had beneficial effects in preventing type 2 DM and NAFLD in experimental animals [19, 20]. It is believed that cynarin, the most crucial active compound of the artichoke extract, is responsible for the cholangiole and choleretic properties of the plant [21]. In Iran, artichoke is sold as tablets under the proprietary name of Atheromod-B®.

Some pharmacological agents improve insulin resistance and hyperlipidemia and increase liver antioxidant defenses, but none is approved for NAFLD [22, 23]. Although recent studies have shown the therapeutic effects of milk thistle and artichoke for certain pathological conditions, the impact of these plants on NAFLD treatment is still unknown. In Iran, the rats were randomly allocated to four groups of ten rats each. They included nondiabetic normal rats (normal group), type 2 diabetic rats (diabetic group), type 2 diabetic rats that received milk thistle (M group), and type 2 diabetic rats that received artichoke (A group).

2. Materials and Methods

2.1. Materials. Livergol® (lot number: 0443) and Atheromod-B® (lot number: 740164) were purchased from Goldaru (Isfahan, Iran) and Barji Essence (Isfahan, Iran) Pharmaceutical Companies, respectively. Livergol® and Atheromod-B® contain the extracts of milk thistle and artichoke, respectively. Streptozotocin (STZ; cat. number: S0130) and nicotinamide (NA; cat. number: N0636) were obtained from Sigma-Aldrich Chemical Company (Steinheim, Germany).

2.2. Animals. Forty male Sprague–Dawley rats (230–250 g) were obtained from the Center of Comparative and Experimental Medicine (Shiraz, Iran). Animals were kept under standard lighting (12-hour light/dark cycles), humidity (35–45%), and temperature (24°C ± 2°C).

The rats were randomly allocated to four groups of ten rats each. They included nondiabetic normal rats (normal group), type 2 diabetic rats (diabetic group), type 2 diabetic rats that received milk thistle (M group), and type 2 diabetic rats that received artichoke (A group).

2.3. Induction of Type 2 Diabetes Mellitus. To induce type 2 diabetes mellitus, NA (110 mg/kg) was injected into animals 15 min before a single intraperitoneal administration of STZ (50 mg/kg). Seven days after induction, fasting blood sugar (FBS) levels were checked using a Glucometer (Accu-check®, Germany) and rats with FBS levels between 126 and 260 mg/dl were considered as type 2 diabetic animals [24]. The confirmation day was considered the first day of diabetes. Four weeks after the confirmation of diabetes, FBS was determined again in all studied groups.

2.4. Treatment. Four weeks after the beginning of diabetes, the milk thistle and artichoke groups received an oral solution of Livergol® (40 mg/kg) and Atheromod-B® (60 mg/kg), respectively, by gavage once a day for eight weeks. Normal and diabetic groups received an equal amount of distilled water.

The daily doses of drugs for the rats were calculated according to the following formula: dose for rats = (X mg/kg × 70 kg/0.018)/0.2 kg or simplified as 6.3 X mg/kg (X = the effective dose for man; 70 kg = the standard weight for man; 0.018 = ratio of the equivalent dose for man and rats based on body surface area; 0.2 kg = the standard weight for rats) [25].

2.5. Oral Glucose Tolerance and Biochemical Assays. At the end of treatments and after a 12 h fast, a glucose solution (2 g/kg body weight, in 0.9% NaCl) was administered to the rats by oral gavage. FBS was measured 0, 30, 60, 90, and 120 min later using the Glucometer [25].

Erythrocyte superoxide dismutase (SOD) activity and malondialdehyde (MDA) serum levels were determined using the SOD ELISA kit (Randox, UK) and Rat MDA ELISA kit (Cusabio Biotech, China), respectively.

The serum activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) and the serum levels of total bilirubin (TB), triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) were measured by routine laboratory methods using an auto-analyzer (Mindray BS-380, China).
2.6. Liver Histological Assay. Twelve weeks from the beginning of diabetes, the animals were sacrificed. The euthanasia protocol was carried out by administration of xylazine (10 mg/kg) and ketamine (75–100 mg/kg) to the rats via intraperitoneal injection. The whole liver was resected and fixed with 10% formalin. The liver was sliced serially at 1 mm thickness, and one slice from the right and left lobes was embedded in tissue capsules. The liver slices were embedded in paraffin, cut into 5 μm sections, and stained with hematoxylin and eosin (H&E). No special staining was done for fat. Samples were observed under a light microscope (Olympus, BX53, Japan) by an expert pathologist in a blind fashion to evaluate the percentage of steatosis. The liver histopathological findings were categorized into three groups: normal, portal tract lymphocytic infiltration, and macrovesicular steatosis.

2.7. Statistical Analysis. Data were presented as mean ± SEM. Statistical analysis was determined using one-way analysis of variance (ANOVA) and paired t-test. If a significant difference was obtained, the source of difference was located by Tukey’s post hoc test. P < 0.05 was considered statistically significant. The statistical analysis was performed by the Statistical Package for Social Sciences version 16 (SPSS Inc, Chicago, IL, USA).

3. Results

3.1. Mortality Rate, Weight Changes, Liver Index, Oral Glucose Tolerance, and Biochemical Assays. At the end of the study, the total mortality rate was 20% (1 in the normal group, 3 in the diabetic group, 2 in the milk thistle group, and 2 in the artichoke group). We measured the weight of rats on the first day (one week after diabetes induction) and the last day (after 12 weeks of diabetic confirmation) and weight changes (the changes between the first day and the last day) and liver index (liver weight divided by body weight) on the last day (Table 1). All groups gained weight significantly, but the comparison among groups revealed that the weight changes were not significant. No difference was seen among groups regarding the liver index (Table 1).

First-day (one week after the induction) FBS and 28th-day FBS of diabetic animals were significantly higher than in normal animals. Blood glucose levels in all three diabetic groups at fasting or 0, 30, 60, 90, and 120 min after glucose administration were significantly higher than those in the normal group (P < 0.001). Milk thistle and artichoke had no significant effect on blood glucose level at the first day and 28th day after diabetes induction and on the oral glucose tolerance test, which was performed at the end of the study (about three months after the induction of diabetes) (Figure 1).

The erythrocyte level of SOD in the diabetic group was significantly lower than in the normal group (P < 0.001). However, these values for milk thistle- and artichoke-treated groups were significantly higher than those for the diabetic group (P < 0.001 and 0.006 for milk thistle and artichoke, respectively). The serum level of MDA in the diabetic group was significantly higher than in the normal group (P < 0.001), but the serum levels of MDA for milk thistle- and artichoke-treated groups were significantly lower than those of the diabetic group (P < 0.001) after the intervention (Table 2).

Serum levels of different lipid profile components were increased significantly (TG and LDL-C) and nonsignificantly (TC) in the diabetic group compared to the normal group (P = 0.001, 0.013, and 0.100, respectively). Administration of milk thistle showed a significant decrease in serum levels of TG, TC, and LDL-C (P < 0.001, P = 0.021, and 0.015, respectively). Administration of artichoke showed a significant decrease in the serum level of TG but not TC and LDL-C (P < 0.001; Table 3).

In our diabetes model, only the AST level rose significantly and was significantly decreased by milk thistle (P = 0.039) but not artichoke (Table 4). The ALT, ALP, and TB levels did not change significantly in diabetic animals (Table 4).

3.2. Liver Histological Assay. Histological samples of rats' liver tissue showed normal lobular architecture with central veins and no prominent inflammation, steatosis, or necrosis in the normal group (Figure 2(a)). The hepatic cord structures were changed in the diabetic group, milk thistle-treated group, and artichoke-treated group, and a noticeable accumulation of fat droplets and steatosis could be found (Figure 2(c)). Some lymphocyte infiltration was observed in the diabetic, milk thistle-treated, and artichoke-treated groups (Figure 2(b)).

4. Discussion

The present study aimed to assess whether milk thistle (Silybum marianum L.) and artichoke (Cynara scolymus L.) administration in streptozotocin-nicotinamide-induced diabetic rats would improve glucose tolerance, biochemical markers, hepatic marker parameters, and plasma oxidative stress and also to investigate whether milk thistle and artichoke administration declined the lipid accumulation in the rat liver.

We established an NAFLD rat model of T2DM using STZ + nicotinamide administration. This combination causes partial necrosis of pancreatic β-cells. The successful induction of the model was confirmed by basal hyperglycemia at one week and four weeks after injections and the impaired glucose tolerance test at the end of the study (Table 2, Figure 1).

Milk thistle and artichoke had no significant effect on the basal glucose level and oral glucose tolerance test (Table 2, Figure 1). Some observed effects in the current study cannot be attributed to diabetes control (see the following). A similar result with silymarin (an active constituent of milk thistle) has been reported, despite its beneficial effect on the liver and pancreas tissues of diabetic rats [26]. However, there are studies in which these plants or their active substances show hypoglycemic effects. These effects have been proposed to result from preserving or repairing pancreatic
beta-cells, decreased insulin resistance, or inhibition of alpha-amylase action [27–30]. The differences in the obtained results may be due to the different doses applied. In our study, the doses were selected based on the recommended dose for hepatoprotection in humans (see methods). However, other causes such as the different experimental models of diabetes and duration of treatment may also have some roles.

In diabetes, lipolysis ensues due to the diminished insulin level and its action. Subsequently, an overload of lipids is deposited in the hepatocytes of animal models, resulting in NAFLD development [31]. In our study, the pathological liver state was categorized as follows (Table 5): normal (normal histological structure of the central vein and surrounding hepatocytes); lymphocyte infiltration (an increase in liver size and hepatocytes with inflammatory cell infiltration), which is the earliest changes detected in the liver in NAFLD [32]; and steatosis (simple hepatic steatosis, also called nonalcoholic fatty liver (NAFL)) that is a relatively benign manifestation of hepatic triglyceride accumulation, with little or no inflammation or liver cell damage [33, 34].

In our study, rat diabetic livers had an obvious accumulation of fat droplets; therefore, steatosis was confirmed (Figure 2(c)).

In this group, AST significantly increased, but no significant changes in ALT, ALP, and TB were observed. In the milk thistle-treated group, fewer and smaller fat droplet accumulation and fewer lymphocytes were observed. In contrast, in the artichoke-treated group, some considerable fat droplet accumulation and steatosis were recognized. In other words, milk thistle showed a mild beneficial effect on the hepatic changes induced by diabetes in the present study and was applied in doses. At the same time, artichoke seemed ineffective in this regard (Table 5).

Several studies have proposed the hepatoprotective effects of silymarin on diabetes [28, 35]. Indeed, histopathological effects and biochemical markers have been more significant than our results in many of them. Again, the differences between the selected doses and the type and experimental model of diabetes may justify these different magnitudes of effects.

There are some reports of hepatoprotective action of artichoke (Cynara scolymus L.) in different hepatotoxicity models, but just a few studies on diabetes-induced hepatic changes could be found. Ben Salem et al. reported hepatoprotective effects of the ethanolic extract of leaves of Cynara scolymus L. in diabetic rats. They attributed it to the antioxidant and hypolipidemic effects of the plant [30].

![Figure 1: Blood glucose changes in the glucose tolerance test (GTT) in each group. Blood glucose values during the GTT were significantly higher in the diabetic groups than in the normal group, which showed insulin resistance in these groups. Values are expressed as the mean ± SEM (n = 7–9/group at each time point). Differences were tested by one-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05 indicates a significant difference with the diabetic control group at the same time points.](image-url)

**Table 1: Weight on the first day and last day, body weight changes, and liver index values.**

| Group         | Weight (g) First day | Weight (g) Last day | Body weight changes (g) | Liver index |
|---------------|---------------------|---------------------|-------------------------|-------------|
| Normal        | 240.2 ± 1.2         | 311.1 ± 7.6         | 70.91 ± 7.07            | 2.7 ± 0.1   |
| Diabetic      | 240.1 ± 1.8         | 305.4 ± 8.6         | 65.3 ± 8.05             | 2.9 ± 0.2   |
| Milk thistle  | 240.3 ± 1.9         | 314 ± 13.3          | 73.7 ± 12.15            | 2.8 ± 0.1   |
| Artichoke     | 238.8 ± 2           | 280.5 ± 14.5        | 41.7 ± 13.6             | 3 ± 0.2     |

Values are expressed as the mean ± SEM (n = 7–9/group). Weight of the first day, the weight of the last day, body weight changes, and liver index. Differences between the weights of the first day and the last day were tested by the paired t test, and ANOVA was used to test the differences of the bodyweight changes and liver index between groups. †P < 0.05 versus first day; ‡P < 0.001 versus first day.

Yao et al. demonstrated that administration of silibinin (principal active constituent of silymarin) in rats with NAFLD for six weeks improves fatty degeneration and inflammation in hepatocytes significantly [25]. In the systematic review of Cicero et al., silymarin improved hepatic lipid accumulation after three months of treatment and decreased the 4-year risk of mortality in cirrhosis patients [36]. A randomized clinical trial displayed that silymarin consumption for three months had better results on liver steatosis than lifestyle changes [37]. A randomized
controlled trial of biopsy-proven NAFLD patients by Loguercio et al. showed that a daily dose of silibinin induces improvement in histological scores of steatosis, inflammation, and fibrosis [38]. Also, silymarin may reduce liver fibrosis in NAFLD patients [39].

In almost all studies in which the hepatoprotective effects (and other valuable actions) of silymarin and artichoke have been reported, their proper mechanism of action is mainly attributed to their antioxidant effects [27, 28, 30, 35, 40, 41]. These drugs have antioxidant effects through increased SOD (an antioxidant enzyme) levels and decreased MDA (a final lipid-oxidized product) levels on NAFLD in rats. Investigations have shown that artichoke is a valuable source of antioxidants that could have applications in preventing...
diseases caused by oxidative damage [42]. The use of silymarin can increase the activity of SOD and decrease MDA levels in mice [43] and has protective effects on oxidative stress markers [44, 45].

Interestingly, while just milk thistle showed some hepatoprotective impact in our study, both plant products showed significant antioxidant action, indicated by increased SOD and decreased MDA (Table 2). Based on these results, it can be proposed that the hepatoprotective effect of milk thistle (and silymarin) is not exclusively due to their antioxidant action and other mechanisms seem to be involved. Anti-inflammatory and antifibrotic activities [41] and an increase in irisin [28], a newly discovered polypeptide, are the proposed mechanisms.

Both plant extracts decreased TG significantly in our study, but only milk thistle decreased TC and LDL-C (Table 3). In addition to the above-mentioned biochemical changes, other studies have also reported significant differences in ALT and ALP [46]. However, we did not observe significant changes in these two parameters in all the studied groups. Administration of silibinin in NAFLD rats for four weeks ameliorated TG, TC, and hepatic steatosis significantly [47]. Salomone et al. performed a similar study in a mouse model of fatty liver in which they investigated an in vitro model of hepatocyte lipotoxicity. They used silibinin to treat NAFLD as a modulator of lipid homeostasis. They concluded that silibinin treatment attenuates steatosis, decreases TG and reactive oxygen species (ROS) production, and markedly reduces lipid accumulation in the liver [48]. Also, artichoke attenuates lipid disturbances and has anti-hypercholesterolemic and hepatoprotection effects [19]. It significantly reduced serum lipid profile and the fatty liver deposition in the hepatic lobule in high-fat-diet-induced obese rats [49].

Based on the obtained results, it seems that milk thistle, but not artichoke, might have some hepatoprotective effects in diabetic rats with NAFLD. Its antioxidant action may contribute to this effect, but other mechanisms are possibly involved. Nonetheless, long-term randomized clinical trials will be necessary to understand whether the observed results can be confirmed. Furthermore, the molecular targets and the signaling transduction pathways of plant extracts should still be more deeply investigated.

5. Conclusion

Our results showed that milk thistle might have some hepatoprotective effects in diabetic rats with NAFLD. Its antioxidant action may contribute to this effect. Milk thistle also effectively protected the liver from lipid accumulation and severe hepatic changes.

5.1. Limitation. One limitation of this study was the short duration to establish and treat the NAFLD rat model. It is better to evaluate the effects of drug treatments in this animal model for a longer time. On the other hand, the strength of our study lies in its histopathologic assessment that could be considered a basis for future clinical trials.

Data Availability

All data are included within the manuscript.

Ethical Approval

This experimental procedure was approved by the Ethics Committee of Shiraz University of Medical Sciences (ethics code: IR.SUMS.REC.1396.1072).

Consent

Not applicable.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors were responsible for conceiving and designing the protocol. AD, MF, and HM designed the study. AD, MF, and AP did the literature search and, together with HM, selected the studies and extracted the relevant data. AD, MHA, and MF synthesized the data. MF and AD wrote the first draft of the manuscript. AD, MHA, MF, AP, and HM provided critical guidance on the analysis and overall direction of the study. All authors critically revised successive drafts of the paper and approved the final version.

Acknowledgments

This work was financially supported by Shiraz University of Medical Sciences (grant no. 15033). The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, and Sheryl Thomas-Nikpoor, Language Editor, Springer Publications, for her valuable comments in editing this manuscript.

References

[1] A. E. Kitabchi, G. E. Umpierrez, J. M. Miles, and J. N. Fisher, “Hyperglycemic crises in adult patients with diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1335–1343, 2009.
[2] L. Abenavoli, N. Milic, and F. Capasso, "Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin,” Endocrine, vol. 42, no. 3, pp. 754-755, 2012.
[3] A. Doostkam, S. Bassiri-Jahromi, and K. Iravani, “Punica granatum with multiple effects in chronic diseases,” International Journal of Fruit Science, vol. 20, no. 3, pp. 471–494, 2020.
[4] S. Chatterjee, K. Khunti, and M. J. Davies, “Type 2 diabetes,” The Lancet, vol. 389, no. 10085, pp. 2239–2251, 2017.
[5] C. Saponaro, M. Gaggini, and A. Gastaldelli, “Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiological mechanisms,” Current Diabetes Reports, vol. 15, no. 6, p. 607, 2015.
[6] P. Angulo, “Nonalcoholic fatty liver disease,” New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002.
[7] T. Graf, M. Wani, R. Agarwal, D. Kroll, and N. Oberlies, “Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (milk thistle) extract in support of preclinical in vivo studies for prostate cancer
Canadian Journal of Gastroenterology and Hepatology

chemoprevention,” *Planta Medica*, vol. 73, no. 14, pp. 1495–1501, 2007.

[8] J. Feher and G. Lengyel, “Silymarin in the prevention and treatment of liver diseases and primary liver cancer,” *Current Pharmaceutical Biotechnology*, vol. 13, no. 1, pp. 210–217, 2012.

[9] P. Ferenčí, B. Dragosics, H. Dittrich et al., “Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver,” *Journal of Hepatology*, vol. 9, no. 1, pp. 105–113, 1989.

[10] M. W. Fried, V. J. Navarro, N. Afshar et al., “Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial,” *JAMA*, vol. 308, no. 3, pp. 274–282, 2012.

[11] S. M. Ross, “Milk thistle (Silybum marianum): an ancient botanical medicine for modern times,” *Holistic Nursing Practice*, vol. 22, no. 5, pp. 299–300, 2008.

[12] J. F. Joy and S. L. Haber, “Clinical uses of artichoke leaf extract,” *American Journal of Health-System Pharmacy*, vol. 64, no. 18, pp. 1906–1909, 2007.

[13] Z. Küskü-Kiraz, G. Mehmetçik, S. Doğru-Abbasoğlu, and M. Uysal, “Artichoke leaf extract reduces oxidative stress and lipoprotein deposition in rats fed on high cholesterol diet,” *Phytotherapy Research*, vol. 24, no. 4, pp. 565–570, 2010.

[14] R. Gebhardt, “Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase pretreatment,” *Phytotherapy Research*, vol. 16, no. 4, pp. 368–372, 2002.

[15] E. Heidarian, E. Jafari-Dehkordi, and A. Seidkhani-Nahal, “Liver-protective effects of Jerusalem artichoke extracts on streptozotocin-induced diabetic rats,” *Journal of Animal and Veterinary Advancements*, vol. 10, no. 19, pp. 2501–2507, 2011.

[16] H. J. Yang, D. Y. Kwon, M. J. Kim, S. Kang, D. S. Kim, and P. Byung-Sung, “Effect of oral administration of jerusalem artichoke (Helianthus tuberosus) in the prevention of the onset of type 2 diabetes and non-alcoholic fatty liver disease in high-fructose diet-fed rats,” *British Journal of Nutrition*, vol. 112, no. 4, pp. 709–717, 2014.

[17] H.-S. Kim and G. D. Han, “Hypoglycemic and hepatoprotective effects of Jerusalem artichoke extracts on streptozotocin-induced diabetic rats,” *Food Science and Biotechnology*, vol. 22, no. 4, pp. 1121–1124, 2013.

[18] Ö. Aksu and B. Altintirim, “Hepatoprotective effects of artichoke (Cynara scolymus),” *Bilim ve Güncilik Dergisi*, vol. 1, no. 2, pp. 44–49, 2013.

[19] K. G. Tolman and A. S. Dalpiaz, “Treatment of non-alcoholic fatty liver disease,” *Therapeutics and Clinical Risk Management*, vol. 3, no. 6, pp. 1153–1163, 2007.

[20] P. Angulo, “Treatment of non-alcoholic fatty liver disease,” *Annals of Hepatology*, vol. 1, no. 1, pp. 12–19, 2002.

[21] A. Shirwalkar, K. Rajendran, and R. Barik, “Effect of aqueous bark extract of Garuga pinnata Roxb. in streptozotocin-nicotinamide induced type-II diabetes mellitus,” *Journal of Ethnopharmacology*, vol. 107, no. 2, pp. 285–290, 2006.

[22] J. Yao, M. Zhi, X. Gao, P. Hu, C. Li, and X. Yang, “Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver,” *Brazilian Journal of Medical and Biological Research*, vol. 46, no. 3, pp. 270–277, 2013.

[23] L. M. O. Miranda, L. D. C. Agostini, W. G. Lima, F. C. Camini, and D. C. Costa, “Silymarin attenuates hepatic and pancreatic redox imbalance independent of glycermic regulation in the alloxan-induced diabetic rat model,” *Biomedical and Environmental Sciences: BES*, vol. 33, no. 9, pp. 690–700, 2020.

[24] A. Amniattalab, H. Malekinejad, A. Rezabakhsh, S. Rokhsartalab-Azar, and S. Alizade-Fanalou, “Silymarin: a novel natural agent to restore defective pancreatic β cells in streptozotocin (STZ)-induced diabetic rats,” *Iranian Journal of Pharmaceutical Research: IJPR*, vol. 15, no. 3, pp. 493–500, 2016.

[25] N. Kheiriipour, J. Karimi, I. Khodadadi, H. Tavilani, M. Taghī Goodarzi, and M. Hashemnia, “Hepatoprotective effects of silymarin on liver injury via irisin upregulation and oxidative stress reduction in rats with type 2 diabetes,” *Iranian Journal of Medical Sciences*, vol. 44, no. 2, pp. 108–117, 2019.

[26] A. G. Alkushi, “Biological effect of Cynara cardunculus on kidney status of hypercholesterolemic rats,” *Pharmacognosy Magazine*, vol. 13, no. 3, pp. S430–S436, 2017.

[27] M. Ben Salem, R. Ben Abdallah Kolsi, R. Dhouibi et al., “Protective effects of Cynara scolymus leaves extract on metabolic disorders and oxidative stress in alloxan-diabetic rats,” *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 328, 2017.

[28] G. Farrell, J. M. Schattenberg, I. Leclercq et al., “Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis,” *Hepatology*, vol. 69, no. 5, pp. 2241–2257, 2019.

[29] E. Ezzeldin, A. A. H. Souror, T. El-Nahhas, A. N. M. M. Soudi, and A. A. Shahat, “Biochemical and neurotransmitters changes associated with tramadol in streptozotocin-induced diabetes in rats,” *BioMed Research International*, vol. 2014, Article ID 238780, 9 pages, 2014.

[30] I. Grattaglione, C. V. Diogo, M. Mastrodonato et al., “A silybin-phenololipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes,” *World Journal of Gastroenterology*, vol. 19, no. 20, pp. 3007–3017, 2013.

[31] F. Bessone, M. V. Razzo, and M. G. Roma, “Molecular pathways of nonalcoholic fatty liver disease development and progression,” *Cellular and Molecular Life Sciences*, vol. 76, no. 1, pp. 99–128, 2019.

[32] T. Mengesha, N. Gnanasekaran, and T. Mehare, “Hepatoprotective effect of silymarin on fructose induced non-alcoholic fatty liver disease in male albino wistar rats,” *BMC Complementary Medicine and Therapies*, vol. 21, no. 1, p. 104, 2021.

[33] A. F. G. Cicero, A. Colletti, and S. Bellentani, “Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence,” *Nutrients*, vol. 10, no. 9, 2018.

[34] R. Aller, O. Izaola, S. Gómez et al., “Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study,” *European Review for Medical and Pharmacological Sciences*, vol. 19, no. 16, pp. 3118–3124, 2015.
[38] C. Loguercio, P. Andreone, C. Brisc et al., “Silybin combined with phosphatidycholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial,” *Free Radical Biology and Medicine*, vol. 52, no. 9, pp. 1658–1665, 2012.

[39] C. Wah Kheong, N. R. Nik Mustapha, and S. Mahadeva, “A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis,” *Clinical Gastroenterology and Hepatology*, vol. 15, no. 12, pp. 1940–1949, 2017.

[40] J. Magielse, A. Verlaet, A. Breynaert et al., “Investigation of the in vivo antioxidative activity of Cynara scolymus (artichoke) leaf extract in the streptozotocin-induced diabetic rat,” *Molecular Nutrition & Food Research*, vol. 58, no. 1, pp. 211–215, 2014.

[41] N. Vargas-Mendoza, E. Madrigal-Santillán, A. Morales-González et al., “Hepatoprotective effect of silymarin,” *World Journal of Hepatology*, vol. 6, no. 3, pp. 144–149, 2014.

[42] W. Biel, R. Witkowicz, E. Piątkowska, and C. Podsiadło, “Proximate composition, minerals and antioxidant activity of artichoke leaf extracts,” *Biological Trace Element Research*, vol. 194, no. 2, pp. 589–595, 2020.

[43] A. Federico, M. Dallio, and C. Loguercio, “Silymarin/silybin and chronic liver disease: a marriage of many years,” *Molecules*, vol. 22, no. 2, 2017.

[44] A. Taleb, K. A. Ahmad, A. U. Ihsan et al., “Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases,” *Biomedicine & Pharmacotherapy*, vol. 102, pp. 689–698, 2018.

[45] J. Roozbeh, B. Shahriyari, M. Akmali et al., “Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis,” *Renal Failure*, vol. 33, no. 2, pp. 118–123, 2011.

[46] K. Kismet, C. Özcan, S. Kuru et al., “Does propolis have any effect on non-alcoholic fatty liver disease?” *Biomedicine & Pharmacotherapy*, vol. 90, pp. 863–871, 2017.

[47] X. Ni and H. Wang, “Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD),” *American Journal of Tourism Research*, vol. 8, no. 2, pp. 1073–1081, 2016.

[48] F. Salomone, I. Barbagallo, J. Godos et al., “Silibinin restores NAD⁺ levels and induces the SIRT1/AMPK pathway in non-alcoholic fatty liver,” *Nutrients*, vol. 9, no. 10, Article ID 1086, 2017.

[49] M. Ben Salem, K. Ksouda, R. Dhouibi et al., “LC-MS/MS analysis and hepatoprotective activity of artichoke (Cynara scolymus L.) leaves extract against high fat diet-induced obesity in rats,” *BioMed Research International*, vol. 2019, Article ID 4851279, 12 pages, 2019.